In contrast, we demonstrated that a single injection of Gel@Cmab/PCZ induced sustained tumor growth inhibition and achieved 91% tumor growth inhibition at markedly lower doses than cetuximab (i.v.)in a CRC PDX model with KRAS mutant. This evidence concerns the gene KRAS and colorectal carcinoma.